Enlivex’s shares cut in half after ‘biases’ cloud Ph2 cell therapy data in sepsis
Enlivex Therapeutics’ cell therapy has disappointed investors because its impact in a mid-stage test in sepsis was difficult to figure out. The company nonetheless said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
